Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APP	ROVAL			
OMB Number:	3235-0287			
Estimated average burden				
hours per respons	e 0.5			

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Name and Address of Reporting Person * Prelack Steven		2. Issuer Name and Ticker or Trading Symbol PIERIS PHARMACEUTICALS, INC. [PIRS]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last) (First) (Middle) C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR			~ ~~~	3. Date of Earliest Transaction (Month/Day/Year) 01/25/2017					Officer (give title below) Other (specify below)				()	
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person Iired, Disposed of, or Beneficially Owned						
BOSTON, MA 02109 (City) (State) (Zip)			Tabla I - Nan-Darivativa Sacuritias Acau											
1.Title of S (Instr. 3)	Security		Date (Month/Day/Year)	2A. Deem Execution any (Month/D	ned Date, if	3. Tran	saction 4. (A 8) (In	Securities Acq or Disposed of astr. 3, 4 and 5)	uired 5. A	Amount of	Securities B ving Reporte	Beneficially 6 cd F	wnership of orm: Express (D) Cr Indirect (D)	Nature of Indirect Geneficial Ownership Instr. 4)
							Persons	s who respor						474 (9-02)
							form dis	ed in this for splays a curr sed of, or Bene	ently vali	d OMB c			e	
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transacti	5. Nu of Deriv Secur Acqu (A) or	mber ative ities ired rosed of . 3, 4,	form dis	splays a curr sed of, or Bend evertible secur ercisable and Date	ently vali	d OMB co	8. Price of		10. Ownershi Form of Derivativ Security: Direct (D or Indirec	Beneficia Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if	4. Transacti	5. Nu of Deriv Secur Acqu (A) or Dispo (D) (Instr	mber ative ities ired rosed of . 3, 4,	form districted, Disposoptions, con 6. Date Exe Exercisable	sed of, or Bendarettion of the security of the	eficially Orities) 7. Title and Amount of Underlying Securities	d OMB co	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownershi Form of Derivativ Security: Direct (D or Indirec	p of Indire Beneficia Ownersh (Instr. 4)

Reporting Owners

Reporting Owner Name / Address	Relationships					
Teoporemg o wher I wante / I wante of	Director	10% Owner	Officer	Other		
Prelack Steven C/O PIERIS PHARMACEUTICALS, INC. 255 STATE STREET, 9TH FLOOR BOSTON, MA 02109	X					

Signatures

/s/ Marc D. Mantell, Attorney-in-fact	01/30/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option will vest in four equal installments on each of March 31, June 30, September 30, and December 31, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.